Risedronate for Paget's Disease of Bone
Risedronate (Actonel - Procter & Gamble), a pyridinyl bisphosphonate, has been approved by the FDA for oral treatment of Paget's disease of bone. Characterized by excessive bone resorption, bony deformity, disorganized bone remodeling and structural weakness, Paget's disease occurs in up to 3% of people older than 55 in Europe and North America (PD Delmas and PJ Meunier, N Engl J Med, 336:558, 1997)....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Risedronate for Paget's Disease of Bone
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1034
Article Code: 1034b
Date: August 28, 1998
Volume: 40
Pages: 87-88
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1034
Article Code: 1034b
Date: August 28, 1998
Volume: 40
Pages: 87-88
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)